Informizely customer feedback surveys

[Skip to content]

Southern Health
Search our Site

EXTRA

A European multi-centre, retrospective, non-interventional study of the effectiveness of Xultophy (insulin degludec/liraglutide) in an adult population with type 2 diabetes 

Novo

This study aims to collect information about the real-world effectiveness and safety of Xultophy in adults with type 2 diabetes.

Xultophy is an insulin treatment for type 2 diabetes that is commercially available in the UK and has been fully approved by regulatory authorities.


What does it involve?

The study involves attending clinic according to usual practice and receiving your usual medical care as agreed by your doctor. 

The study does not require of you anything additional during your participation, only data readily available in your medical records will be collected.  


Inclusion Criteria

  • Diagnosed with Type 2 diabetes
  • Xultophy has been prescribed as treatment for your diabetes at least six months prior to your inclusion in the study. 
  • Aged ≥18 years old


To refer potential participants or to request further information, please contact the research team:

Email: Amy.Thomas@Southernhealth.nhs.uk

Phone: 023 8047 5258

I would like to:

Return to Diabetes studies page

Return to current studies

Call the research team on 02380 475 258 

Email the research team